Michael Tomsicek, M.B.A., has served on our board of directors since October 2022. Mr. Tomsicek has served as a member of the board of directors of Milestone Pharmaceuticals USA, Inc., a Nasdaq-listed biopharmaceutical company, since April 2019. Mr. Tomsicek served as the Chief Financial Officer of CRISPR Therapeutics AG, a Nasdaq-listed gene editing company, from November 2017 through October 2021. Prior to that, Mr. Tomsicek served as Chief Financial Officer of Abiomed, Inc., a Nasdaq-listed medical device company, from July 2015 to August 2017. Before that, he was Chief Financial Officer at Cubist Pharmaceuticals, Inc., or Cubist, a Nasdaq-listed biopharmaceutical company. He was at Cubist from August 2010 to January 2015, through the company’s sale to Merck, and held a series of roles of increasing responsibility leading finance, investor relations and strategic sourcing. Prior to Cubist, Mr. Tomsicek spent nearly eight years at General Electric Healthcare, ultimately as Chief Financial Officer of the global ultrasound business. Mr. Tomsicek holds an M.B.A. and a B.S. in Engineering, both from the University of Wisconsin.
Christopher LeMasters, M.B.A, joins Acrivon Therapeutics, Inc. as Chief Business Advisor, with over 30 years of business operational and transactional leadership experience, including 23 years in the pharmaceutical industry. Chris most recently served as EVP and COO of Amplyx Pharmaceuticals where he led the successful sale of the company to Pfizer in April 2021. Prior to that, he was EVP and CBO at Mirati Therapeutics where he oversaw the successful expansion of the company and its market capitalization from $100 million to $5 billion in January 2020.
Prior to joining Mirati, Chris served as CEO of Promosome, a private mRNA re-engineering and biotherapeutics company co-founded by Nobel Laureate Dr. Gerald M. Edelman. Additionally, he has held senior management positions at several biotherapeutics companies, most recently as co-founder and CBO of Tragara Pharmaceuticals, a clinical-stage cancer therapeutics company. He also served as co-founder and CBO of Cabrellis Pharmaceuticals, Inc., where he negotiated its acquisition by Pharmion Corporation for $104 million, and as vice president, corporate development of Conforma Therapeutics, where he negotiated its acquisition by Biogen IDEC for $250 million. Previously, Chris worked in the corporate business development group at Eli Lilly & Company where he was involved in numerous partnerships and licenses across a range of therapeutic areas. Earlier in his career, he was a management consultant with Coopers & Lybrand Consulting and an operational auditor with Owens Corning.